Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, in combination with Alimta(R) (pemetrexed) and in combination with Taxotere(R) (docetaxel) as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the Eighth International Lung Cancer Congress in Wailea, Hawaii.

The first ongoing study is evaluating Xcytrin plus Alimta and has enrolled 27 patients of which 20 are evaluable for response at this time. Patients are receiving 15mg/kg Xcytrin with a standard dose of Alimta and treatment is repeated every 21 days. Seventeen patients (85%) receiving Xcytrin and Alimta have achieved stabilization of their tumors, with 10 of the 17 still on treatment for up to nine cycles. The median survival time and median time to progression have not been reached, with estimated actuarial survival of 69% at 12 months. Patients still on treatment remain under evaluation for tumor response. The most common severe (Grade 3 or higher) side effects were asthenia (10.3%), pneumonia (10.3%), thrombocytopenia (10.3%), and neutropenia (6.9%).

The other ongoing study is evaluating Xcytrin plus Taxotere and has enrolled 24 patients of which 14 are evaluable for response at this time. Patients are given 15mg/kg Xcytrin with a standard dose of Taxotere and treatment is repeated every 21 days. Thirteen patients (87%) receiving Xcytrin and Taxotere have achieved stabilization of their tumors, with four still on treatment. The median survival time is 8.2 months and the median time to progression is 8.7 months. Patients still on treatment remain under evaluation for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... organiser UBM Live , a division of UBM ... CPhI Japan events line-up that is set to return ... March, 2012. The Pharmatech Japan event, which focuses on ... veterinary and medical industries, will join the Japan Pharma ...
... Pharmaceuticals, Inc. (Nasdaq: AUXL ) today announced ... Capital Global Healthcare Conference to be held March 13-14, ... Sargent, Vice President, Investor Relations and Corporate Communications, is ... its product pipeline at 8:00 a.m. ET on Tuesday, ...
Cached Medicine Technology:New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 2New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 3Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference 3Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference 4
(Date:7/13/2014)... Athletes with a certain genetic make-up are ... to research presented today at the American Orthopaedic Society ... research marks the first of its kind investigating a ... events that occur after a head injury. , ... the (GT)n genotype were four times more likely to ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers ... released its new range of elegant Quinceanera dresses ... at discounted prices. Worldwide clients can enjoy this special ... company’s online shop, there are plenty of beautiful dresses ... great materials. MyDressCity.com’s hot items are prom gowns, bridesmaid ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... 13, 2014 A decreased ability to identify ... and Alzheimer,s disease, while examinations of the eye ... associated with Alzheimer,s, in the brain, according to ... at the Alzheimer,s Association International Conference 2014 (AAIC ... studies, the decreased ability to identify odors was ...
Breaking Medicine News(10 mins):Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... Rajasthan High Court issued notice to the state government ... silicosis. ,The public interest litigation (PIL), filed ... pleaded that the labor force needed to be protected ... of the state government and the malpractice of the ...
... $100,000 of their money to help// construct the first modern ... the donation to the Duk Lost Boys Clinic through the ... spring and serve more than 150,000 people. ... "lost boys" of Sudan who is the director of non-profit ...
... governments to join the anti-tuberculosis global plan, which would ... disease has become extremely drug-resistant. ,Ban's message ... on Saturday. The World Health Organization (WHO) recently reported ... of tuberculosis, XDR-TB, which threatens to derail efforts to ...
... An alarming 20 percent of the people availing re-treatment of ... India. According to a leading global health advocacy, India witness ... the eve of the World TB Day, March 24, the ... TB drug resistance is becoming a major threat for several ...
... harmful for pregnant women and may cause degeneration of their ... ,The musculoskeletal system gives human beings and animals the ability ... The cardiovascular system is composed of the heart, blood vessels, ... the blood. ,Doctors often advice women to ...
... Court about its plan to technologically upgrade its forensic ... up all its vacancies to facilitate quick investigation into ... appearing before a bench of Justice T.S. Thakur and ... steps to fill up about 45 vacancies in the ...
Cached Medicine News:Health News:Public Interest Litigation Filed Favoring Mineworkers Against Silicosis 2Health News:Tuberculosis Drug Resistance 'alarming' in India 2Health News:Rohini Forensic Lab to Be Upgraded 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: